drugset / Trial / NCT02117427
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)
Phase 1/2
Completed
11 enrolled
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
Timeline
- Start
- 2014-05-27
- Primary completion
- 2016-06-30
- Completion
- 2017-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MDGN201 TARGTEPO | Unknown | — | — |